Testing fianlimab with cemiplimab for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This study compares a new combination of two drugs (fianlimab and cemiplimab) against cemiplimab alone for people with head and neck cancer that has returned or spread. It aims to see if the combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have head and neck cancer that started in the mouth, throat, voice box, or lower throat and cannot be cured with local treatments.
- Your tumor has a protein called PD-L1 at a certain level (CPS of 1 or more).
- You have at least one tumor that can be measured on scans.
- You are able to do most of your daily activities (ECOG score 0 or 1).
- You have not had systemic cancer therapy for advanced disease before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a second immunotherapy drug (CDX-1140) to the standard immunotherapy cemiplimab before surgery is better than cemiplimab alone for people with stage III-IV head and neck cancer that can be removed with surgery.
This trial tests a combination of two immunotherapy drugs (cemiplimab and fianlimab) for people with newly diagnosed, advanced head and neck cancer that hasn't spread to distant parts of the body. The goal is to see if this treatment can help shrink or control the cancer.
This trial tests two immunotherapy drugs (cemiplimab and fianlimab) designed to help your immune system fight nasopharyngeal cancer. The study focuses on a specific type of nasopharyngeal cancer that is associated with Epstein-Barr virus (EBV), and aims to determine if this combination treatment is safe and effective.
This trial compares two different immunotherapy approaches for people with HPV-positive oropharyngeal cancer who have completed initial treatment like surgery, radiation, or chemotherapy. The goal is to see which option works better to keep the cancer from coming back, and eligibility is determined by a special blood test that detects HPV DNA.
This Phase 1 trial tests how well cemiplimab (an immune treatment) can work when combined with chemotherapy and an additional immunotherapy for certain head and neck cancers. It may help shrink the cancer and improve outcomes, while also checking safety and dosing.
This Phase 1 trial tests cemiplimab (an immune system medicine) given with “induction” chemotherapy before the main treatment for locally advanced squamous cell head and neck cancer. It’s designed to see how well this treatment is tolerated and to learn about immune responses that may help future patients.
Hear when a new Head and Neck Squamous Cell Carcinoma (HNSCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.